West Pharma Surges on Q2 Beat, Raises 2025 Outlook

West Pharmaceutical Services (NYSE:WST) reported strong Q2 2025 results, with adjusted earnings of $1.84 per share and revenue of $766.5 million, both exceeding analyst expectations. The company's performance was driven by high demand for GLP-1 weight-loss and diabetes drug components, with its High-Value Product segment accounting for nearly half of total sales and growing 11.3%. West raised its full-year 2025 adjusted profit guidance to $6.65–$6.85 per share and increased its sales outlook to $3.04–$3.06 billion. Shares surged as much as 24% following the announcement, one of the largest single-day gains on record for the company. West also announced a new CFO appointment and reduced its projected tariff impact for 2025. Despite a year-to-date decline in the stock, this marks four consecutive quarters of earnings and revenue beats, highlighting sustained operational strength.